BPC-157: Mechanism of Action and Research Summary

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

What Is BPC-157?

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein BPC. The "157" designation refers to its position within the parent protein. It consists of 15 amino acids and is notable for its remarkable stability in biological environments, particularly in the presence of gastric acid, which distinguishes it from many other peptides studied in preclinical research contexts.

First described in research emerging from the University of Zagreb in the 1990s, BPC-157 has since become one of the more extensively studied synthetic peptides in animal model research. The breadth of biological processes it appears to interact with, spanning gastrointestinal protection, connective tissue repair, angiogenesis, and neurological signaling, has made it a subject of sustained scientific interest.

This post summarizes the current state of BPC-157 research, with a focus on its proposed mechanisms of action and the in-vitro and animal model studies that have examined its biological activity. All discussion is framed strictly within the context of preclinical research.

Chemical Properties

Researchers sourcing BPC-157 should be familiar with its core chemical identifiers:

CAS Number: 137525-51-0
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.53 g/mol
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Form: Typically supplied as a lyophilized (freeze-dried) white powder
Solubility: Soluble in aqueous buffers; acetic acid may be used to aid dissolution in certain laboratory protocols

The peptide’s proline-rich sequence contributes significantly to its proteolytic stability. Proline residues create structural rigidity that resists enzymatic degradation, which is a key reason BPC-157 retains detectable activity even when administered orally in animal models, an unusual property for a peptide of its class.

Mechanism of Action

The pharmacology of BPC-157 is multi-pathway and context-dependent, which both complicates simple characterization and explains the breadth of effects observed across different tissue models. Several interconnected mechanisms have been identified or proposed in the literature.

Nitric Oxide (NO) and NOS System Modulation

One of the most consistently reported mechanisms involves BPC-157’s interaction with the nitric oxide synthase (NOS) system. Research has demonstrated that BPC-157 can upregulate endothelial NOS (eNOS) activity, leading to increased local nitric oxide production. This is significant because NO plays a central role in vascular tone, platelet aggregation, and the early stages of tissue repair.

Sikiric and colleagues have published extensively on how BPC-157’s protective effects in gastric and vascular models appear to be mediated, at least in part, through NO pathways. Studies using NOS inhibitors (such as L-NAME) have shown attenuation of BPC-157’s effects, supporting the NO-dependence of certain observed outcomes. Importantly, the relationship does not appear to be straightforwardly agonistic: BPC-157 has shown the capacity to counteract the effects of both NO overproduction and NO deficiency in animal models, suggesting a modulatory rather than simply stimulatory role.

Growth Factor Modulation: VEGF and FGF

BPC-157 research has consistently implicated vascular endothelial growth factor (VEGF) upregulation as a central mechanism in its pro-angiogenic and wound-healing associated effects. VEGF is a primary driver of new blood vessel formation (angiogenesis), and enhanced VEGF expression has been documented in tendon fibroblasts, endothelial cells, and gastrointestinal tissue following BPC-157 exposure in animal models.

In a study published by Hsieh et al. (2015) in the Journal of Orthopaedic Research, BPC-157 was found to accelerate tendon-to-bone healing in rats, with associated increases in VEGF expression at the repair site (PMID: 25916160).

Fibroblast growth factor (FGF) modulation has also been reported in dermal and musculoskeletal models, suggesting BPC-157 may recruit multiple growth factor pathways simultaneously rather than relying on a single upstream signal.

FAK-Paxillin Pathway

The focal adhesion kinase (FAK) and paxillin signaling pathway represents one of the more mechanistically specific findings in BPC-157 research. FAK is a non-receptor tyrosine kinase that plays a central role in cell migration, proliferation, and survival. Paxillin is a scaffolding protein that coordinates signaling at focal adhesion complexes.

Research from Tvrdeic et al. and associated groups has indicated that BPC-157 activates FAK and upregulates paxillin expression in fibroblasts and endothelial cells. This is mechanistically coherent with the observed enhancement of cell migration in wound-healing assays, as FAK-paxillin signaling is a known regulator of the cytoskeletal rearrangements required for directed cell movement.

Dopamine System Interactions

An often-overlooked aspect of BPC-157 research is its apparent interaction with dopaminergic signaling. Animal model studies have investigated BPC-157 in the context of dopamine-related behavioral and neurological outcomes, including models of dopamine dysregulation induced by antipsychotics or neurotoxins.

Sikiric’s group has published data suggesting BPC-157 can counteract dopamine-depletion syndromes and modulate dopamine receptor sensitivity in rodent models (reviewed in Sikiric et al., Current Neuropharmacology, 2017; PMID: 28901270).

Published Research Summary

The following represents a curated overview of key preclinical studies. All findings are derived from animal models or in-vitro systems and have no established translation to human clinical outcomes.

Gastrointestinal Tract Protection

The GI tract is arguably the most extensively studied tissue in BPC-157 research. Studies in rat models have examined BPC-157’s effects on gastric ulceration, inflammatory bowel disease models, and intestinal anastomosis healing. Sikiric et al. demonstrated significant reduction in NSAID-induced gastric lesion area in rat models treated with BPC-157, with effects attributed to enhanced mucosal blood flow via NO-dependent pathways.

Wound Healing and Dermal Repair

Multiple research groups have examined BPC-157 in excisional wound models. In-vitro studies using human dermal fibroblasts have documented enhanced migration in scratch assays, increased collagen synthesis, and upregulated expression of wound-healing associated genes. Chang et al. (2011) published data in the Journal of Applied Physiology examining BPC-157 effects on muscle healing following crush injury in rats (PMID: 21817113).

Tendon and Ligament Repair

Tendon and ligament research constitutes a major area of BPC-157 investigation, largely due to the poor intrinsic healing capacity of these tissues. Krivic et al. (2006) demonstrated accelerated Achilles tendon healing in rat transection models, with BPC-157-treated animals showing superior biomechanical strength and histological organization compared to controls (PMID: 16609824).

Neuroprotection

In rodent models of traumatic brain injury, spinal cord injury, and peripheral nerve crush, BPC-157 administration has been associated with improved functional outcomes and reduced markers of neuronal injury. Gjurasin et al. (2010) examined peripheral nerve regeneration following transection in rats (PMID: 20638416), finding superior functional recovery in treated animals.

Purity and Quality Considerations

For researchers sourcing BPC-157, peptide quality is a non-negotiable methodological variable. Impure or incorrectly synthesized peptide will produce unreliable results and may introduce confounding variables that invalidate experimental conclusions.

Reputable suppliers should provide a Certificate of Analysis (COA) for each batch that includes at minimum:

HPLC Purity: Research-grade peptide should typically show greater than 98% purity by HPLC.
Mass Spectrometry Confirmation: Mass spec data confirms the compound’s molecular weight matches the expected value for BPC-157 (1419.53 g/mol).
Endotoxin Testing: A COA should include a Limulus Amebocyte Lysate (LAL) or equivalent endotoxin test result, typically expressed in EU/mg.
Moisture/Water Content: Lyophilized peptides retain some residual moisture that affects actual peptide content by weight.

Maple Research Labs provides full third-party COA documentation for all peptide products. When evaluating any supplier, request the COA before purchase and verify the testing laboratory is independent of the manufacturer.

Storage and Handling for Laboratory Use

Lyophilized (Dry) Form:

Recommended storage: -20°C in a desiccated environment, protected from light
At -20°C, lyophilized peptide is generally considered stable for 24 months or longer when properly sealed
Avoid repeated freeze-thaw cycles of the dry powder
Minimize exposure to humidity

Reconstitution for Laboratory Use:

BPC-157 is typically reconstituted in sterile bacteriostatic water or phosphate-buffered saline (PBS) for in-vitro applications
Once reconstituted, solutions should be aliquoted into single-use volumes where possible
Reconstituted solutions stored at -20°C are generally considered stable for 3-6 months
Never store reconstituted peptide solutions at room temperature for extended periods

Research Context and Disclaimer

The information presented in this post is intended solely to summarize the existing preclinical scientific literature on BPC-157. All studies referenced involve animal models or in-vitro systems. The biological mechanisms described are proposed models derived from that preclinical data and do not represent established human pharmacology.

BPC-157, as supplied by Maple Research Labs, is sold exclusively for laboratory research purposes. It has not been approved by Health Canada, the FDA, or any other regulatory authority for therapeutic, diagnostic, or preventive use in humans or animals. It is not a drug, supplement, or food product.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

References cited: PMID 25916160, PMID 21817113, PMID 16609824, PMID 20638416, PMID 28901270. Maple Research Labs does not endorse or make claims based on the findings of these studies as they pertain to human use.

Related Research Products

Explore the research-grade peptides discussed in this article, each available with batch-specific Certificates of Analysis and same-day shipping across Canada:

Browse All Research Peptides | Research Peptide Comparison Guide